Prognostic role of 18F-FDG PET-CT in the prone position in the evaluation of invasive breast carcinoma
Mastology (Online)
; 31: 1-6, 2021.
Article
em En
|
LILACS-Express
| LILACS
| ID: biblio-1363669
Biblioteca responsável:
BR2499.9
ABSTRACT
Introduction:
The objective of this study was to correlate the features of invasive breast carcinoma in 18F-FDG positron emission tomography/computed tomography with histopathological results, findings from other imaging methods, and survival.Methods:
This observational single-center study included patients who underwent staging 18F-FDG positron emission tomography/ computed tomography between September 2012 and April 2019; the results were correlated with the findings of other imaging tests and anatomopathological results. Lesions were evaluated for their maximum standardized uptake value on positron emission tomography/computed tomography performed in the prone position. Tumors were classified into three subtypes (luminal, HER2 and triple-negative) based on immunohistochemical analyses.Results:
A total of 125 patients with a mean age of 52 years (2490 years) were analyzed. The primary tumor showed an increased 18F-FDG concentration on positron emission tomography/computed tomography in 122 (97.6%) patients, with a mean maximum standardized uptake value of 7.15 (1.032.9 range). The mean maximum standardized uptake value was higher in the triple-negative subtype (11.4; n=24) than in the luminal (6.2; n=89) and HER2 (5.0; n=9) subtypes (p<0.01). Tumors with more aggressive histological and immunohistochemical characteristics showed higher maximum standardized uptake values. Patients with a standardized uptake value greater than 7 in the primary tumor or greater than 6.7 in the axillary lymph nodes had poor overall survival (p=0.03 and p<0.01, respectively).Conclusions:
Our study suggests that the maximum standardized uptake value obtained on positron emission tomography/computed tomography in the prone position may correlate with the tumor immunophenotype and overall survival regardless of the treatments performed, and can be used as a prognostic biomarker in invasive breast carcinoma patients
Texto completo:
1
Coleções:
01-internacional
Base de dados:
LILACS
Tipo de estudo:
Prognostic_studies
Idioma:
En
Revista:
Mastology (Online)
Ano de publicação:
2021
Tipo de documento:
Article